Table 1.
Patient, Disease, and Prior Treatment Characteristics
| Characteristic | Number (%) |
|---|---|
| Age [median (range)] | 72 (51–95) |
| Gender | |
| Male | 12 (46%) |
| Female | 14 (54%) |
| Histology | |
| Hepatocellular carcinoma | 12 (46%) |
| Intrahepatic cholangiocarcinom | 12 (46%) |
| Biphenotypic hepatobiliary tumor | 2 (8%) |
| Reason for unresectability | |
| Patient factors | 11 (42%) |
| Tumor factors | 11 (42%) |
| Patient/Tumor factors | 4 (1 6 %) |
| Cirrhosis | 15 (58%) |
| Child Pugh Class A | |
| Child Pugh score 5 | 17 (65%) |
| Child Pugh score 6 | 6 (23%) |
| Child Pugh Class B (score 7) | 3 (12%) |
| Baseline laboratory values [median (range)] | |
| Bilirubin (mg/dl) | 0.6 (0.3 – 3) |
| Albumin (g/dl) | 3.9 (2.6 – 4.7) |
| INR | 1.12 (0.9 – 1.49) |
| AST (U/L) | 55 (24 – 123) |
| ALT (U/L) | 51 (14 – 167) |
| Creatinine (mg/dl) | 0.79 (0.46 – 1.87) |
| Platelets (1000/mm3) | 122 (52 – 3) |
| Alkaline Phosphatase (U/L) | 116 (70 – 420) |
| AFP (HCC only) | 48 (<5 – 4472) |
| ECOG performance status | |
| 0 | 1 (4%) |
| 1 | 21 (80%) |
| 2 | 2 (8%) |
| 3 | 1 (4%) |
| Prior therapies# | |
| Surgery | 2 (8%) |
| Radiofrequency ablation | 1 (4%) |
| TACE | 8 (31%) |
| Microwave ablation | 1 (4%) |
| Chemotherapy | 9 (35%) |
| AJCC T stage (IHC/biphenotypic) | |
| T1 | 7 (50%) |
| T2 | 5 (36%) |
| T3 | 1 (7%) |
| T4 | 1 (7%) |
| BCLC stage (HCC) | |
| A1 | 1 (8%) |
| A2 | 0 (0%) |
| A3 | 1 (8%) |
| A4 | 3 (25%) |
| B | 4 (33%) |
| C | 3 (25%) |
| Number of lesions | |
| 1 | 22 (84%) |
| 2 | 3 (12%) |
| 3 | 1 (4%) |
| Tumor vascular thrombosis | 7 (27%) |
| Tumor diameter [median (range)] (cm) | 5.0 (1.6 – 12.3) |
| ≤2 cm | 3 (12%) |
| 2–4 cm | 7 (27%) |
| 4–6 cm | 6 (23%) |
| 6–8 cm | 6 (23%) |
| 8–10 cm | 3 (12%) |
| >10 cm | 1 (4%) |
#
Some patients received multiple therapies prior to SBRT